Boehringer provides update on iclepertin Phase III program in schizophrenia

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met.1–6 Overall, no statistically significant effects on cognition or functioning were observed in patients treated with iclepertin versus placebo at six months.1 All three trials demonstrated that iclepertin, a glycine transporter 1 (GlyT1) inhibitor, was generally well tolerated, with a safety profile that remains consistent with previous studies.1,2,7

“While these findings are disappointing, we remain dedicated to finding effective solutions for those living with serious mental illnesses. Our innovative pipeline includes over 20 additional investigative therapies in all stages of development and in different disease areas including schizophrenia and major depressive disorder,” said Shashank Deshpande, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “In the near future more can be expected. Our gratitude goes to the patients and clinical investigators whose time and commitment made this research possible.”  

CONNEX was the largest program for cognitive impairment in schizophrenia to date. Boehringer believes that the results will aid scientific understanding and inform future research for patients living with cognitive impairment in schizophrenia, an area of high unmet need with no approved targeted pharmaceutical treatment options available.8,9 Full efficacy and safety data will be submitted for presentation at an upcoming medical meeting. 

About cognitive impairment in schizophrenia 

Schizophrenia affects approximately 24 million people worldwide.10 Cognitive impairment is one of the three core symptom domains of schizophrenia, along with positive and negative symptoms.11 Cognitive impairment affects more than 80% of people with this condition, manifesting early in patients’ lives, and representing a leading cause of disability and impairment in daily functioning.8,9,12 People with schizophrenia often face cognitive challenges that impact their problem-solving abilities, attention and memory.8,9 These problems can make it difficult to live an independent and productive life.8,9 They can also cause a person to struggle with simple tasks such as attending appointments, which can make treatment difficult.8,9 

There are no approved targeted pharmaceutical treatments for cognitive impairment in schizophrenia.8,9

About iclepertin and the CONNEX clinical program 

Iclepertin (BI 425809), an investigational oral inhibitor of glycine transporter 1 (GlyT1), was studied as a potential treatment for cognitive impairment in adults with schizophrenia.1–6 Iclepertin has not been approved by any regulatory authorities.  

CONNEX was a Phase III clinical program designed to assess the safety and efficacy of iclepertin for improving cognitive impairment in adults with schizophrenia.2–6 The program comprised three clinical trials, all of which were randomized, double-blind, placebo-controlled parallel group trials investigating treatment with oral iclepertin 10 mg once daily over a 26-week period in adults with schizophrenia who received stable antipsychotic treatment.2–6 The CONNEX clinical program enrolled 1,840 patients in 41 countries.4–6  

Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately.13

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com. 

Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. 

References: 

Boehringer Ingelheim. Data on File. Rosenbrock H, Desch M, Wunderlich G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1557–1566. doi:10.1007/s00406-023-01576-z. Falkai P, Reuteman-Fowler C, Blahova Z, Ikezawa S, Marder SR, Krystal JH. Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme. Eur Psychiatry. 2023;66(Suppl 1):S637. doi:10.1192/j.eurpsy.2023.1325. ClinicalTrials.gov. NCT04846868. Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1). Available from: https://clinicaltrials.gov/study/NCT04846868. Accessed January 2025. ClinicalTrials.gov. NCT04846881. Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2). Available from: https://clinicaltrials.gov/study/NCT04846881. Accessed January 2025. ClinicalTrials.gov. NCT04860830. CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia. Available from: https://clinicaltrials.gov/study/NCT04860830. Accessed January 2025. Fleischhacker WW, Podhorna J, Gröschl M, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021;8(3):191–201. doi:10.1016/S2215-0366(20)30513-7. Kitchen H, Rofail D, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther. 2012;29(2):148–162. doi:10.1007/s12325-012-0001-4. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2(4):531–536. doi:10.2147/nedt.2006.2.4.531. World Health Organization. Schizophrenia. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Accessed January 2025. Stahl SM. Stahl’s Essential Psychopharmacology. 4th ed. Cambridge University Press; 2013. Mosiołek A, Gierus J, Koweszko T, Szulc A. Cognitive impairment in schizophrenia across age groups: a case-control study. BMC Psychiatry. 2016;16:37. doi:10.1186/s12888-016-0749-1. ClinicalTrials.gov. NCT05211947. A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study. Available from: https://clinicaltrials.gov/study/NCT05211947. Accessed January 2025.


Attachment

  • Boehringer healthcare HCP

Boehringer provides update on iclepertin Phase III program in schizophrenia


THỦ THUẬT HAY

Cách bỏ quan tâm hàng loạt các Official Account không cần thiết trên Zalo của bạn

Các tài khoản Official Account (OA) là những tài khoản của cộng đồng hay các doanh nghiệp trên Zalo nhằm gửi thông tin bạn có thể đang quan tâm để tăng tương tác giữa người dùng và các trang thông tin đó.

7 môi trường Desktop dành cho người dùng Linux

Không có một môi trường Desktop nào được coi là chính thức cho Linux và cũng không giống như hệ điều Windows, người dùng Linux có quyền lựa chọn giữa nhiều môi trường Desktop khác nhau, tất cả đều mang những phong cách

Cách tải file Torrent bằng Internet Download Manager(IDM )

Các file Torrent luôn đặc biệt và gây ra những vấn đề khó chịu với người dùng. Ngoài ra, chúng ta cũng khó có thể tải về máy tính những file này theo cách thông thường.

Hướng dẫn bạn cách đăng nhập Windows 11 bằng vân tay

Sử dụng cảm biến vân tay thay vì mã PIN hoặc mật khẩu thông thường để bảo mật và đăng nhập máy tính chạy Windows 11 là cách nhanh và bảo mật nhất? Dưới đây là hướng dẫn để đăng nhập vào Windows 11 bằng vân tay.

Hướng dẫn cập nhật iOS 11.2 beta 5, pin vẫn chưa ổn

Rất có thể đây là bản beta cuối cùng của nhánh 11.2 trước khi Apple phát hành ra kênh chính thức.

ĐÁNH GIÁ NHANH

Đánh giá nhanh Galaxy S8 Plus: Màn hình 6,2 inch, chống nước IP68

Như vậy là Samsung Galaxy S8 đã trình làng đến người dùng vào tối ngày 29/03/2017 vừa qua. Bên cạnh phiên bản thường, S8 Plus sở hữu màn hình to hơn nhưng kích thước lại được tối ưu hóa rất tốt.

Với 3 camera, Samsung Galaxy A7 (2018) sẽ làm được những gì?

Samsung Galaxy A7 (2018) đang là cái tên rất hot thời điểm hiện tại khi chiếc điện thoại này có tới 3 camera sau và mức giá hợp túi tiền với đại đa số người dùng.

Razer Blade 15 (2018): Thanh mảnh nhưng vẫn mạnh mẽ như cỗ máy PC gaming thực thụ

Năm nay, Razer đã cách mạng hóa dòng Blade lên hẳn một tầm cao mới, hãng đã bỏ hoàn toàn phiên bản 14-inch để thay thế phiên bản 15-inch, nhưng kích thước vẫn gần như không thay đổi nhờ viền màn hình siêu mỏng, và đây